Lifestyle
- Regular exercise
- Adequate sleep
- Stress management
- Avoidance of infections
Immunoglobulin G · IgG
IgG quantifies the concentration of immunoglobulin G antibodies in the blood.
Reference ranges may vary slightly by laboratory and age.
Immunoglobulin G (IgG) is a type of antibody, representing the most common form of immunoglobulin found in blood circulation. It plays a crucial role in the body's immune response by identifying and neutralizing foreign objects like bacteria and viruses. IgG is produced by plasma cells and is involved in both primary and secondary immune responses, providing long-term immunity and memory against pathogens. Clinically, IgG levels are important in diagnosing and monitoring immune disorders. Elevated IgG levels can indicate chronic infections, autoimmune diseases, or multiple myeloma, while low levels may suggest immunodeficiency disorders. In the context of athletic performance and biohacking, IgG levels can reflect an individual's immune status and resilience to infections, which can be crucial for maintaining optimal health and performance. Additionally, researchers have explored the role of IgG glycosylation patterns in aging, suggesting potential links to inflammaging and longevity. However, IgG measurements can be influenced by factors such as recent infections, vaccinations, and individual genetic variability. It is important to consider these confounders when interpreting IgG levels. No specific fasting or time-of-day requirements are typically necessary for IgG testing, but consistent testing conditions are recommended for accurate monitoring over time.
Klinische Bedeutung
Elevated IgG levels may indicate chronic infections, autoimmune diseases, or multiple myeloma. Reduced IgG levels can suggest immunodeficiency disorders or protein-losing conditions.
Progressively rising IgG levels may suggest worsening of chronic infections or autoimmune activity. Re-test in 4-6 weeks if levels are outside the normal range.
Progressively falling IgG levels may indicate improving immune status or response to treatment in conditions like multiple myeloma.
Re-test Interval
4-6 weeks if outside optimal range
Note:
Consult a healthcare provider before starting any new supplement regimen, especially if you have underlying health conditions.
Testing Frequency
Annually for general health monitoring, more frequently if monitoring a specific condition.
Current research suggests that reference ranges for immunoglobulin G (IgG) in various contexts, such as autoimmune disorders and aging, remain inadequately defined, leading to potential misinterpretation of results. Researchers have not yet established optimal targets for IgG glycosylation patterns as biomarkers for healthy aging or inflammatory diseases. Additionally, clinical questions regarding the long-term implications of IgG antibody presence in conditions like neuromyelitis optica and the role of IgG in diverse inflammatory responses remain unanswered.
1,027
Total Citations
6
Human/RCT
12.8
Avg. Influence
2025
Latest
Researchers described a novel autoimmune disorder characterized by glial fibrillary acidic protein (GFAP)-IgG as a biomarker. In a study of 102 patients, they found that GFAP-IgG positivity is highly specific for an autoimmune CNS disorder and can indicate a need for immunotherapy. The study also noted that certain imaging features were prevalent among patients.
Researchers found that the glycosylation patterns of Immunoglobulin G (IgG) vary significantly with age and disease states, making it a potential biomarker for general health. They noted that changes in IgG glycosylation can influence immune function and may play a role in disease progression, suggesting its analysis could enhance existing disease biomarkers.
Researchers found that intrathecal immunoglobulin G (IgG) synthesis is crucial for diagnosing multiple sclerosis (MS). They highlighted the effectiveness of κ-free light chains (FLCs) as a new biomarker, showing similar diagnostic accuracy to traditional methods. The study recommends including κ-FLC synthesis in MS diagnostic criteria for improved evaluation.
Researchers reviewed high-throughput methods for analyzing Immunoglobulin G (IgG) glycosylation, which is important for understanding its functional relevance in health and disease. They emphasized the need for robust and affordable methodologies to facilitate the discovery of glycan biomarkers in clinical settings.
Researchers reviewed the role of Immunoglobulin G (IgG) glycans in aging, highlighting their potential as biomarkers and molecular effectors. They summarized studies on how IgG glycosylation patterns change with age and discussed the implications of these changes for understanding the aging process and age-related diseases.
Researchers discussed the relationship between glycosylation of immunoglobulin G (IgG) and aging. They found that changes in IgG glycopatterns may influence inflammation levels and could serve as biomarkers for healthy aging. The study emphasizes the potential of IgG glycosylation in understanding aging processes.
Researchers reviewed biochemical biomarkers for multiple sclerosis (MS), emphasizing the importance of immunoglobulin G oligoclonal bands (OCB) in diagnosis. They noted that kappa free light chains (FLC) may offer higher sensitivity and specificity than OCB, highlighting the need for diverse biomarkers in MS evaluation.
Researchers summarized the impact of Immunoglobulin G (IgG) glycosylation on tumor immunity and progression. They noted that specific glycosylation modifications correlate with tumor characteristics, suggesting that IgG glycosylation could be a target for improving tumor diagnosis and treatment strategies.
Researchers reviewed the role of neuromyelitis optica immunoglobulin G (NMO-IgG) as a specific biomarker for distinguishing neuromyelitis optica from multiple sclerosis. They confirmed the presence of NMO-IgG in various populations and highlighted its incorporation into new diagnostic criteria, enhancing understanding of the disease.
Researchers investigated the prognostic value of plasma immunoglobulin G (IgG) N-glycome traits in pulmonary arterial hypertension (PAH). They found that specific IgG fucosylation traits can predict survival in PAH patients, suggesting that these biomarkers can enhance risk assessment in clinical settings.
Research publications about Immunglobulin G over time
10totalLog lab results, track trends and optimize your biomarkers over time.
This page is for informational and research purposes only. All information is based on published scientific literature and does not constitute medical advice, diagnosis, or treatment recommendations. Many substances listed may not be approved for human use and may be subject to drug regulation laws (e.g., AMG in Germany, FDA in the US). PepStack does not encourage the use of any substance on humans. Always consult a qualified healthcare professional before making any health-related decisions. Use of this information is entirely at your own risk. PepStack assumes no liability for the accuracy, completeness, or timeliness of the content provided. Full disclaimer